Certificate course in Cardiovascular Pharmacology

Diuretics form a key antihypertensive group, lowering blood volume and sodium. Thiazides serve as first-line; indapamide works at low doses with fewer metabolic effects; loop diuretics suit severe cases.

Explore sympathoplegics that reduce sympathetic nervous system activity to prevent hypertension by diminishing central outflow, blocking autonomic ganglia, depleting neurotransmitters, and inhibiting adrenergic receptors.

Explain how alpha-2 agonists and beta-1 antagonists reduce central sympathetic outflow to treat hypertension, highlighting clonidine, alpha-methyldopa, and newer imidazoline receptor drugs like moxonidine and rilmenidine.

Ganglion blockers inhibit nicotinic nn receptors in ganglia, lowering blood pressure by reducing sympathetic transmission, with dry mouth and urinary retention as adverse effects; examples include hexamethonium, trimethoprim, and mecamylamine.

Block alpha one receptors with selective or non-selective adrenergic antagonists to cause vasodilation and lower blood pressure, aiding hypertension management and benign prostatic hyperplasia, including pheochromocytoma crises.

Beta blockers block beta-1 receptors to reduce cardiac output, renin release, central sympathetic outflow, and raise cyclin levels to promote vasodilation, especially with cardioselective beta-1 blockers in hypertension with diabetes.

Nitric oxide releasing vasodilators, including sodium nitroprusside and hydralazine, promote vasodilation. Sodium nitroprusside is short acting and IV for hypertensive emergencies; prolonged use risks cyanide toxicity and hypothyroidism.

Nimodipine is a cerebral selective vasodilator reversing vasoconstriction after subarachnoid hemorrhage. Clevidipine is an ultra short-acting dihydropyridine for hypertensive emergencies.

renin inhibitors directly inhibit renin, blocking angiotensinogen to angiotensin I conversion and lowering blood pressure; drugs like aliskiren and remikiren are taken orally for chronic hypertension.

Explore how ACE inhibitors block angiotensin I to II conversion, raise bradykinin, and reduce proteinuria, with drug profiles, uses, and key adverse effects.

Angiotensin receptor blockers (losartan, valsartan, irbesartan, candesartan, telmisartan, eprosartan) antagonize angiotensin II at AT1 receptors, do not raise bradykinin, reducing cough and angioedema, and inhibiting the distal Ras pathway.

We outline safe antihypertensives for pregnancy using the better mother care mnemonic: beta blockers (cardioselective and labetalol), methyldopa, clonidine, dihydropyridine calcium channel blockers, hydralazine, and prazosin.

Explore hypertension with coexisting conditions and the corresponding drug choices, including beta blockers, calcium channel blockers, ACE inhibitors, ARBs, diuretics, and alpha blockers.

Explore how myocardial ischemia from obstructed, vasospastic, or microvascular coronary flow causes angina pectoris, and how anti-anginal drugs target heart rate, blood pressure, and myocardial oxygen demand.

Classify antianginal drugs into nitrates, calcium channel blockers, beta blockers, potassium channel openers, fatty acid oxidation inhibitors, and sodium channel blockers, and discuss their mechanisms and clinical use.

Explore nitrates as antianginals, detailing the nitric oxide–cGMP mechanism, venous-dominant dilation that reduces preload, ischemic blood flow redistribution, and dipyridamole’s coronary steal phenomenon.

Describe nitrate administration routes—sublingual for acute angina relief, oral or transdermal for prophylaxis; note duration, first-pass metabolism, and cyanide toxicity via methemoglobin.

Explain major adverse effects of nitrates, including tachycardia, flushing, and headache. Discuss tolerance by route, eight-hour drug-free periods, and the risk of profound hypotension with phosphodiesterase inhibitors such as sildenafil.

Trimetazidine inhibits fatty acid oxidation, boosts glucose use, and reduces lipid peroxidation to protect the myocardium in angina. Ranolazine blocks late sodium current, first-line for chronic angina with QT risk.

Explore the three angina types: stable angina from coronary atherosclerosis, unstable angina from plaque rupture with platelet aggregation and coagulation, and Prinzmetal angina from coronary vasospasm.

Variant angina arises from coronary vasospasm that acutely reduces blood flow. Use sublingual nitrate for acute attacks; dihydropyridines and nitrates for prophylaxis; avoid aspirin and beta blockers, which worsen vasospasm.

Classify heart failure into preserved and reduced ejection fraction based on contractile function, explaining diastolic heart failure (preserved EF) and systolic heart failure (reduced EF).

Explore etiologies of heart failure with reduced ejection fraction, defined by ejection fraction under 40%, including coronary artery disease, chronic pressure/volume overload, dilated cardiomyopathy, and viral or Chagas infections.

Explore heart failure with preserved ejection fraction, a diastolic heart failure with normal ejection fraction. Identify etiologies such as hypertrophic and restrictive cardiomyopathy, aging, and cor pulmonale from pulmonary disease.

Explain the left heart failure clinical features, including reduced cardiac output and pulmonary congestion with dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Note basal crepitations, oliguria, and S3 signs.

Master congestive heart failure management through lifestyle changes and drugs, including diuretics, inotropes, and beta blockers, plus ACE inhibitors or ARBs and aldosterone antagonists to relieve symptoms and improve survival.

Assess fluid retention in heart failure; use diuretics if present, otherwise start ACE inhibitors and beta blockers in NYHA classes, then add aldosterone antagonists, nitrates, or digoxin if symptoms persist.

Explore nonpharmacological heart failure treatments, including biventricular pacing (cardiac resynchronization therapy) and implantable cardioverter defibrillator (ICD), and surgical options like left ventricular aneurysmectomy, left ventricular assist devices, and cardiac transplantation.

Identify and manage precipitating factors, including infections, anemia, pregnancy, thyrotoxicosis, arrhythmias, myocarditis, myocardial infarction, accelerated hypertension, pulmonary embolism, drugs such as beta blockers, disopyramide, corticosteroids, NSAIDs, salt, stress, and noncompliance.

Explore how the cardiac action potential varies across the SA node, AV node, and ventricular muscle, highlighting automaticity, pacemaker activity, resting membrane potential, and potassium’s role.

Explore phase zero of the cardiac action potential, including Vmax and fast sodium channel states, and how resting membrane potential shapes excitability and arrhythmia risk.

Explore phase one inactivation of fast sodium channels and downward deflection from potassium and chloride, phase two plateau from calcium–potassium balance, and phase three repolarization; relate to ECG.

Class i a antiarrhythmics block sodium and potassium channels, delay repolarization, and prolong action potential duration, leading to torsades de pointes; examples include quinidine, procainamide, disopyramide.

Quinidine, a class one agent derived from the cinchona plant, has anti-malarial action poorer than quinine. It can cause nausea, vomiting, diarrhea, hypotension, and hypoglycemia.

Class I C antiarrhythmics are most potent sodium channel blockers with negligible potassium channel effects and slow kinetics, used for resistant ventricular tachycardia and WPW syndrome, with radiofrequency ablation.

Class two agents are beta blockers that block beta-1 receptors on the heart, lowering sympathetic activity and slowing AV nodal conduction to treat supraventricular tachycardias; esmolol, propranolol, metoprolol are examples.

Class three antiarrhythmic agents block potassium channels to prolong repolarization and action potential duration, lengthening QT interval and risking torsades de pointes, with reverse use dependence favoring prevention of tachyarrhythmias.

Explores class iii antiarrhythmics—amiodarone and dronedarone, vernakalant, bretylium, sotalol, and ibutilide—covering adverse effects, non-iodinated options, atrial fibrillation indications, and acute conversion.

Explore class five antiarrhythmics such as digoxin and adenosine; digoxin increases vagal activity to control ventricular rate in atrial fibrillation, while adenosine treats paroxysmal supraventricular tachycardia by AV node hyperpolarization.

Identify the drug of choice for acute and chronic therapy across arrhythmias. Ibutilide converts to sinus rhythm; amiodarone is for chronic use except in torsades de pointes and digitalis-induced cases.

Learn about primary hyperlipoproteinemia types 1–5, their increasing lipoproteins (chylomicrons, VLDL, LDL), and how triglyceride and cholesterol elevations relate to atherosclerosis risk, with statins, fibrates, nicotinic acid, and fenofibrate.

Explore how dyslipidemia arises from hyperlipoproteinemia and review first-line anti dyslipidemic drugs—statins, bile acid binding resins, and intestinal cholesterol absorption inhibitors—along with second-line agents fibrates and niacin.

Statins, first-line antihyperlipidemic drugs, inhibit HMG-CoA reductase to lower hepatic cholesterol and upregulate LDL receptors, reducing LDL, triglycerides, IDL, and VLDL while raising HDL, with no effect on lipoprotein a.

Explore how ezetimibe inhibits the NPC1L1 transporter to reduce intestinal cholesterol absorption, raise hepatic LDL receptor synthesis, and treat type IIa and IIb hyperlipoproteinemia alone or with statins.

Understand bile acid binding resins—cholestyramine, colestipol, and colesevelam—that bind bile acids in the intestinal lumen, reduce plasma bile acids, and increase hepatic LDL receptors to lower cholesterol.

Fibric acid derivatives activate PPAR alpha to upregulate lipoprotein lipase, lowering triglycerides and raising HDL; fenofibrate is a prodrug with strong LDL reduction and uricosuric effects, used for hypertriglyceridemia.

Newer dyslipidemia drugs include probucol, with antioxidant action inhibiting LDL oxidation and lowering LDL and HDL cholesterol, and Google lipid, which modestly lowers LDL and raises HDL, causing diarrhea.